about
Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data.Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.Population-based mechanistic prediction of oral drug absorptionAbundance of Hepatic Transporters in Caucasians: A Meta-Analysis.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineCharacterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter.Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs.In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug DispositionBreast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates With Estrone-3-Sulfate Transport in Caco-2.Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method.pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers.Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure.Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells.PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small InfantsAssessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic ModelingComment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions"In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2Lost in centrifugation: accounting for transporter protein losses in quantitative targeted absolute proteomicsRisk-Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling ApproachMetformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactionsThe Permeation of Acamprosate Is Predominantly Caused by Paracellular Diffusion across Caco-2 Cell Monolayers: A Paracellular Modeling ApproachUse of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug SubstratesPhysiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and RecommendationsProteomic Quantification of Human Blood-Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia PatientsPreincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug InteractionsThe Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis
P50
Q31103506-9FA9E708-6191-45D5-8A1E-68223C86874DQ33994570-CC0C79DD-6E7E-4C24-B2AC-CFAF79E4FB00Q36806598-F17C9834-87EF-4601-899F-17A1148CC9F0Q36935249-6ACC5D49-08F2-4FCE-9322-7E60C479EC19Q36935254-7F3572F7-1788-4D27-A085-223BC2B90BCCQ37214520-FB0287D9-E3DE-40C5-8547-9B96569C01AAQ37279044-A5E1E48E-69DD-46F8-B37E-78A538D6CCF0Q37394474-30F5D2CB-C943-49A7-A881-9495205255BEQ37470663-0CA27039-63F4-4AEE-80DA-2627D403A80BQ37660713-33370392-021C-4565-BA5A-28EF1BFFE884Q37824348-FD3B8046-3FE3-46FE-9AE0-EA05C6EB8539Q38196655-3785102B-6835-42E2-969D-71ACE1B4EAE1Q38773640-7C3EBFB3-FF15-4F35-9392-419C576E4461Q38796858-272436E8-1AE0-4B8B-B8F1-BB2599A4686DQ39940520-C01A7F07-1BCC-45B8-BEEB-D09982DE055BQ40260228-90A8C10D-82D7-4A4D-8978-D743C1A4B8E8Q44568322-3E5E934D-CD54-46C6-9834-56C2D79C7B95Q45284897-5BC554DA-76E5-411B-BCA6-D6C715B5ED76Q46505252-D789F8EE-061D-4A97-B6E2-90CB1DC63961Q48168817-D634033F-FF62-4035-AE16-69C82734D489Q49720145-1D20AED5-ACD5-4939-9953-78C86FB51101Q51956668-063A78DB-25FD-4295-B276-E3FB590B2B57Q61847182-7FB1AC35-37B2-4006-85DA-C0590BA58318Q64104355-CAB113DF-0CEF-487E-BD37-2747E5A5D7B1Q86415506-0D4C8AB5-21F8-4820-AAFA-3EEF0A7EF513Q86847487-5266CEB4-D306-418D-AC49-168029E3FDBFQ87442369-B4D39310-9878-479D-B317-71174E47030DQ88325268-E1130250-3B87-4EFC-BD6F-DA46F66AC7E7Q89071328-76B79BEC-8DA1-4CBC-9C53-F2CF0A49DC9EQ90328575-CFD6C296-DE4D-4312-94D3-56605DDB134FQ90737007-BE9BDC2B-4AEE-487C-9BA4-38B313C75244Q90816208-8AF076FE-366F-4E6C-8AA1-456057400601Q91418279-9C9A8901-4D47-4354-B9A5-5F793F0C45C0Q91706956-F0A1D1A2-B946-4A0D-ACDE-297539BDBA79Q91928764-005D44AC-E08E-4363-8125-A090E3232C2C
P50
description
researcher
@en
wetenschapper
@nl
name
Sibylle Neuhoff
@en
Sibylle Neuhoff
@nl
type
label
Sibylle Neuhoff
@en
Sibylle Neuhoff
@nl
prefLabel
Sibylle Neuhoff
@en
Sibylle Neuhoff
@nl
P106
P31
P496
0000-0001-8809-1960